<p>Immunome, Inc.（纳斯达克代码：IMNM - 获取免费报告）在周一的盘中交易中股价创下 52 周新高。该公司股价最高达到 19.05 美元，最后交易价格为 19.1150 美元，成交量为 267180 股。该股票此前收盘价为 18.53 美元。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>3 只具有巨大增长潜力的小型股</li>
</ul>
<p>几位股票分析师对该股进行了评论。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Immunome 的 “卖出（d-）” 评级。高盛集团在 9 月 22 日的研究报告中开始覆盖 Immunome 的股票。他们对该股给予了 “买入” 评级，并设定了 26.00 美元的目标价。Wedbush 在 11 月 7 日的研究报告中重申了对 Immunome 的 “跑赢大盘” 评级，并设定了 21.00 美元的目标价。摩根大通在 8 月 7 日的报告中将 Immunome 的目标价从 23.00 美元下调至 22.00 美元，并对该股设定了 “增持” 评级。最后，Guggenheim 在 8 月 25 日的研究报告中重申了对 Immunome 的 “买入” 评级，并设定了 25.00 美元的目标价。九位分析师对该股给予了买入评级，一位分析师则给予了卖出评级。根据 MarketBeat 的数据，Immunome 的共识评级为 “适度买入”，共识目标价为 23.78 美元。</p>
<p><strong>阅读我们关于 IMNM 的最新研究报告</strong></p>
<h2>Immunome 股价上涨 0.6%</h2>
<p>该公司的 50 日简单移动平均线为 14.41 美元，200 日简单移动平均线为 11.15 美元。该股票的市值为 17.1 亿美元，市盈率为-6.32，贝塔值为 1.96。</p>
<p>Immunome（纳斯达克代码：IMNM - 获取免费报告）最近在 11 月 6 日宣布了其季度财报。该公司报告的季度每股收益为（0.65 美元），低于分析师的共识预期（0.57 美元）0.08 美元。Immunome 的净利润率为-1687.08%，股本回报率为-76.50%。作为一个整体，研究分析师预测 Immunome, Inc.在本财年将发布-2.21 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近对该公司的持仓进行了调整。大都会人寿投资管理公司在第一季度将其在 Immunome 的持仓增加了 19.1%。大都会人寿投资管理公司现在拥有 42411 股该公司的股票，价值 285,000 美元，此前在该期间内增持了 6792 股。Adage Capital Partners GP L.L.C.在第一季度将其在 Immunome 的持仓提高了 55.0%。Adage Capital Partners GP L.L.C.现在拥有 775,000 股该公司的股票，价值 5,216,000 美元，此前在该期间内增持了 275,000 股。Exome Asset Management LLC 在第一季度购买了 Immunome 的新股份，价值 1,776,000 美元。Y Intercept Hong Kong Ltd 在第二季度收购了 Immunome 的新股份，价值 793,000 美元。最后，查尔斯·施瓦布投资管理公司在第一季度将其在 Immunome 的持仓增加了 34.4%。查尔斯·施瓦布投资管理公司现在拥有 614,387 股该公司的股票，价值 4,135,000 美元，此前在该期间内增持了 157,135 股。机构投资者和对冲基金持有该公司 44.58% 的股份。</p>
<h2>Immunome 公司简介</h2>
<p>（获取免费报告）</p>
<p>Immunome, Inc.是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在进行的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期临床试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种针对成纤维细胞活化蛋白的放射性配体疗法；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Immunome</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>Hims、Block 和 NRG 刚刚启动了巨额股票回购</li>
<li>外汇是什么，如何运作？</li>
<li>零售财报汇总：沃尔玛表现出色，塔吉特在第三季度下滑</li>
<li>一些最佳的大型股有哪些？</li>
<li>摩根大通和高盛在国防驱动需求展望中升级 MP 材料</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Immunome 吗？</h2>
<p>在考虑 Immunome 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Immunome 并不在名单上。</p>
<p>虽然 Immunome 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMNM

<p>Immunome, Inc.（纳斯达克代码：IMNM）达到了新的 52 周高点，交易价格为 19.1150 美元。分析师的评级意见不一：Weiss Ratings 给出了 “卖出” 评级，而高盛等则给予 “买入” 评级，目标价格高达 26 美元。该股票的市值为 17.1 亿美元，市盈率为-6.32。机构投资者增加了持股比例，44.58% 的股票由他们持有。尽管整体共识为适度买入，但一些分析师建议更好的投资选择</p>

<p>Immunome, Inc. (NASDAQ:IMNM - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $19.05 and last traded at $19.1150, with a volume of 267180 shares. The stock had previously closed at $18.53.</p>
<div class="lb-trans"><p>Immunome, Inc.（纳斯达克代码：IMNM - 获取免费报告）在周一的盘中交易中股价创下 52 周新高。该公司股价最高达到 19.05 美元，最后交易价格为 19.1150 美元，成交量为 267180 股。该股票此前收盘价为 18.53 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>3 Small-Cap Stocks With Big Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有巨大增长潜力的小型股</li>
</ul>
</div><p>Several equities analysts have commented on the stock. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Immunome in a report on Wednesday, October 8th. The Goldman Sachs Group assumed coverage on shares of Immunome in a research note on Monday, September 22nd. They issued a &#34;buy&#34; rating and a $26.00 price objective on the stock. Wedbush restated an &#34;outperform&#34; rating and set a $21.00 price objective on shares of Immunome in a research report on Friday, November 7th. JPMorgan Chase &amp; Co. reduced their target price on Immunome from $23.00 to $22.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, August 7th. Finally, Guggenheim reiterated a &#34;buy&#34; rating and issued a $25.00 price target on shares of Immunome in a research note on Monday, August 25th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Immunome has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $23.78.</p>
<div class="lb-trans"><p>几位股票分析师对该股进行了评论。Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Immunome 的 “卖出（d-）” 评级。高盛集团在 9 月 22 日的研究报告中开始覆盖 Immunome 的股票。他们对该股给予了 “买入” 评级，并设定了 26.00 美元的目标价。Wedbush 在 11 月 7 日的研究报告中重申了对 Immunome 的 “跑赢大盘” 评级，并设定了 21.00 美元的目标价。摩根大通在 8 月 7 日的报告中将 Immunome 的目标价从 23.00 美元下调至 22.00 美元，并对该股设定了 “增持” 评级。最后，Guggenheim 在 8 月 25 日的研究报告中重申了对 Immunome 的 “买入” 评级，并设定了 25.00 美元的目标价。九位分析师对该股给予了买入评级，一位分析师则给予了卖出评级。根据 MarketBeat 的数据，Immunome 的共识评级为 “适度买入”，共识目标价为 23.78 美元。</p>
</div><p><strong>Read Our Latest Research Report on IMNM</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 IMNM 的最新研究报告</strong></p>
</div><h2>Immunome Stock Up 0.6%</h2>
<div class="lb-trans"><h2>Immunome 股价上涨 0.6%</h2>
</div><p>The business's 50 day simple moving average is $14.41 and its two-hundred day simple moving average is $11.15. The stock has a market cap of $1.71 billion, a P/E ratio of -6.32 and a beta of 1.96.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 14.41 美元，200 日简单移动平均线为 11.15 美元。该股票的市值为 17.1 亿美元，市盈率为-6.32，贝塔值为 1.96。</p>
</div><p>Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Immunome（纳斯达克代码：IMNM - 获取免费报告）最近在 11 月 6 日宣布了其季度财报。该公司报告的季度每股收益为（0.65 美元），低于分析师的共识预期（0.57 美元）0.08 美元。Immunome 的净利润率为-1687.08%，股本回报率为-76.50%。作为一个整体，研究分析师预测 Immunome, Inc.在本财年将发布-2.21 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Management LLC increased its position in Immunome by 19.1% in the 1st quarter. MetLife Investment Management LLC now owns 42,411 shares of the company's stock valued at $285,000 after acquiring an additional 6,792 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Immunome by 55.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company's stock worth $5,216,000 after purchasing an additional 275,000 shares during the period. Exome Asset Management LLC bought a new stake in shares of Immunome in the first quarter worth $1,776,000. Y Intercept Hong Kong Ltd acquired a new stake in Immunome in the second quarter valued at $793,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Immunome by 34.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 614,387 shares of the company's stock valued at $4,135,000 after purchasing an additional 157,135 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持仓进行了调整。大都会人寿投资管理公司在第一季度将其在 Immunome 的持仓增加了 19.1%。大都会人寿投资管理公司现在拥有 42411 股该公司的股票，价值 285,000 美元，此前在该期间内增持了 6792 股。Adage Capital Partners GP L.L.C.在第一季度将其在 Immunome 的持仓提高了 55.0%。Adage Capital Partners GP L.L.C.现在拥有 775,000 股该公司的股票，价值 5,216,000 美元，此前在该期间内增持了 275,000 股。Exome Asset Management LLC 在第一季度购买了 Immunome 的新股份，价值 1,776,000 美元。Y Intercept Hong Kong Ltd 在第二季度收购了 Immunome 的新股份，价值 793,000 美元。最后，查尔斯·施瓦布投资管理公司在第一季度将其在 Immunome 的持仓增加了 34.4%。查尔斯·施瓦布投资管理公司现在拥有 614,387 股该公司的股票，价值 4,135,000 美元，此前在该期间内增持了 157,135 股。机构投资者和对冲基金持有该公司 44.58% 的股份。</p>
</div><h2>Immunome Company Profile</h2>
<div class="lb-trans"><h2>Immunome 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.</p>
<div class="lb-trans"><p>Immunome, Inc.是一家生物技术公司，开发靶向癌症疗法。该公司的临床资产包括 AL102，一种正在进行的伽马分泌酶抑制剂，目前正在进行针对纤维瘤的三期临床试验；前临床资产包括 IM-1021，一种受体酪氨酸激酶样孤儿受体 1 和抗体药物偶联物，以及 IM-3050，一种针对成纤维细胞活化蛋白的放射性配体疗法；以及 IM-4320，一种抗 IL-38 免疫疗法候选药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Immunome</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
<li>What is Forex and How Does it Work?</li>
<li>Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Immunome</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>Hims、Block 和 NRG 刚刚启动了巨额股票回购</li>
<li>外汇是什么，如何运作？</li>
<li>零售财报汇总：沃尔玛表现出色，塔吉特在第三季度下滑</li>
<li>一些最佳的大型股有哪些？</li>
<li>摩根大通和高盛在国防驱动需求展望中升级 MP 材料</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunome Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Immunome 吗？</h2>
</div><p>Before you consider Immunome, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Immunome 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Immunome 并不在名单上。</p>
</div><p>While Immunome currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunome 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immunome（纳斯达克代码：IMNM）创下 12 个月新高 - 以下是原因